Compare BioNTech SE - ADR (BNTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Western Alliance Bancorporation — how do they compare? BioNTech SE - ADR trades at $90.49 (market cap $22.86B), while Western Alliance Bancorporation trades at $81.27 (market cap $8.77B). The key difference: BioNTech SE - ADR is far larger — about 2.6× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WAL | |
|---|---|---|
Market Cap | $22.86B | $8.77B |
Sector | Health | Financials |
52-Week High | $119.34 | $96.08 |
52-Week Low | $83.89 | $66.70 |
Enterprise Value | $6.53B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Western Alliance Bancorporation (WAL) trades at $80.49, down 0.25% on the day, with a bearish technical signal and mixed fundamentals. The stock shows strong analyst support with a consensus price target of $90.67 and 79% buy ratings, but recent earnings beats are overshadowed by negative operating cash flow and high interest expenses. Recent news highlights strategic lending growth and industry recognition, including a #1 bank ranking in Arizona by Forbes in June 2026.
The outlook is cautiously optimistic given Wall Street's bullish stance and valuation discounts, but risks include cash flow pressures and macroeconomic sensitivity. Upside hinges on execution of lending growth and margin improvement, while downside could stem from credit quality deterioration or rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
